Registry of Hospitalized Patients Treated With Fondaparinux
Status
Conditions
Details and patient eligibility
About
Registry of Hospitalized patients at Brigham and Women's Hospital treated with Fondaparinux
Full description
The use of antithrombotic agents in the hospital is the mainstay of therapy for the treatment or prophylaxis of venous thromboembolism (VTE) and acute coronary syndrome (ACS). Concern with the administration of heparins and risk for adverse sequelae has led to the development of newer, longer-acting agents. Fondaparinux offers once daily administration with only an extremely small risk of developing heparin induced thrombocytopenia.
Recent data have further demonstrated the efficacy and safety of Fondaparinux in VTE and ACS, expanding its use in clinical practice. We aim to: 1) determine how Fondaparinux is being used in a "real life" clinical setting, a tertiary-care academic medical center (BWH), and 2) assess the associated clinical outcomes at 90 days after initiation of Fondaparinux.
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
- BWH hospitalized patients receiving Fondaparinux
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal